Adaptimmune Therapeutics plc American Depositary Shares
Symbol: ADAP (NASDAQ)
0.05
▲ (16.47%) 0.007
Company Description:
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
Key Stats
- Today's Open: $0.0445
- Today's High: $0.0517
- Today's Low: $0.0417
- Today's Volume: 26.11M
- Yesterday Close: $0.0425
- Yesterday High: $0.046
- Yesterday Low: $0.0403
- Yesterday Volume: 28.91M
- Last Min Volume: 2.47K
- Last Min High: $0.0495
- Last Min Low: $0.0493
- Last Min VWAP: $0.049307
Company Profile
- Name: Adaptimmune Therapeutics plc American Depositary Shares
- Website: https://www.adaptimmune.com
- Listed Date: 2015-05-06
- Location: ABINGDON, OXFORDSHIRE, X0
- Market Status: Active
- CIK Number: 0001621227
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $11.26M
- Round Lot: 100
- Outstanding Shares: 265.05M
- Asset Type: ADRC
RECENT FILINGS FOR ADAP
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-08 | 8-K | View |
| 2025-09-03 | 4 | View |
| 2025-09-02 | 144 | View |
| 2025-08-29 | 4 | View |
| 2025-08-29 | 144 | View |
| 2025-08-29 | 8-K | View |
| 2025-08-19 | 4 | View |
| 2025-08-19 | SCHEDULE 13D/A | View |
| 2025-08-19 | SCHEDULE 13G/A | View |
| 2025-08-15 | 8-K | View |
| 2025-08-15 | 144 | View |
| 2025-08-15 | 144 | View |
| 2025-08-14 | 8-K | View |
| 2025-08-13 | SCHEDULE 13G/A | View |
| 2025-08-13 | 10-Q | View |
| 2025-08-13 | 8-K | View |
| 2025-08-07 | 8-K | View |
| 2025-07-31 | 8-K | View |
| 2025-07-30 | 4 | View |
| 2025-07-28 | 8-K | View |
Latest News on ADAP